Altimmune appoints Christophe Arbet-Engels as CMO; Dr. Scott Harris to retire as Senior Strategic Advisor by Feb 2026

Altimmune, Inc.

Dr. Scott Harris stepped down as CMO effective Oct 1, 2025; will serve as Senior Strategic Advisor until retirement on Feb 28, 2026.
Christophe Arbet-Engels, MD, PhD joined as CMO effective Oct 1, 2025.
Transition Agreement provides Harris continued salary, benefits, equity vesting, and FY2025 bonus eligibility subject to release and compliance.
Harris's stock option exercise period extended to 12 months after separation date.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.